Christine Korsgaard

The rofécoxib is a Médicament Anti-inflammatoire not stéroïdien ( AINS ) of the class of the Coxib S which was used in the treatment of the Ostéoarthrite, of the acute states painful, and of the Dysménorrhée. Examples of trade names: Vioxx® , Vioxx-Dolor® . It was withdrawn from the market in 2004 because of problems involved in an increased risk of Myocardial infarction (on a world level on September 30th, 2004) .

It was introduced in 1999 by the multinational Merck, and was available on ordinance in seal and drinkable suspension.

Only in the United States, one estimates that more than 20 million people used it.

Selective inhibiter COX-2

Like any molecule of this class, it has an action anti-inflammatory drug and appreciably less undesirable effects gastric (burns, ulcer), but more risk to develop cardiovascular diseases.

Contrary to the Aspirine and the inflammatory anti not stéroïdiens traditional, it does not modify the Sécrétion of Thromboxane A2. Moreover, it decreases the rate of circulating Prostacycline, the latter being vasodilator. the plate aggregability is then increased.

Side effects

principal article: Coxib

Withdrawal of the market

Study of the FDA

A study of the American administration of the foodstuffs and Médicament S ( Food & Drug Administration FDA) concluded that 27.785 deaths and cardiac problems could be caused by Vioxx between 1999 and 2004. It is only after this study that Merck then decided to withdraw Vioxx of the market, although many preceding studies indicated big risks following the use of this drug.

Study VIGOR

Rofecoxib, tested in Double blind man against the Naproxène on 2000 patients over nine months, a traditional anti-inflammatory drug, shows a doubling of the number of Myocardial infarction. The initial explanation was a " effect; protecteur" naproxene, which does not have, in fact, ever shown.

APPROVe study

Rofecoxib was tested on 2600 patients, against a placebo, over 3 years. The study was stopped in an early way in front of quasi doubly of the number of myocardial infarction in the treated group. This study was the pretext with the stop of the marketing of the molecule.

Withdrawal

The withdrawal of the molecule gave place to important controversies on information circulation, and blaming the pharmaceutical laboratory.

It seems that Rofecoxib comprises serious side effects, especially in the event of prolonged catch or of predisposing ground. The other COXIBS are not free of the same effects, even if they are numerically rarer.

See too

Random links: